Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Phase 3 Completed 1604 enrolled Bryan Cotton NHS Blood and Transplant · collab Queen Mary University of London · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).

Timeline

Start: 2017-01
Primary completion: 2021-12-01
Completion: 2022-11-01

Publications

Results Davenport R, Curry N, Fox EE, Thomas H, Lucas J, Evans A, Shanmugaranjan S, Sharma R, Deary A, Edwards A, Green L, Wade CE, Benger JR, Cotton BA, Stanworth SJ, Brohi K; CRYOSTAT-2 Principal Investigators. Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial. JAMA. 2023 Nov 21;330(19):1882-1891. doi: 10.1001/jama.2023.21019.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cryoprecipitate	Protein / enzyme biologic	3 unknown	—
Background	BLOOD, WHOLE	Other / unclassified	—	—
Background	Plasma	Other / unclassified	—	—
Background	Platelets	Other / unclassified	—	—
Background	red blood cells	Unknown	—	—

Indications

No indication recorded.